



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/617,927	07/10/2003	Dennis M. Brown	A-71604/RFT/THR (468899-3)	3972
32940	7590	03/28/2006	EXAMINER LILLING, HERBERT J	
DORSEY & WHITNEY LLP 555 CALIFORNIA STREET, SUITE 1000 SUITE 1000 SAN FRANCISCO, CA 94104			ART UNIT	PAPER NUMBER
1651				

DATE MAILED: 03/28/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT      PAPER

20060328

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

Commissioner for Patents


Attached is the PTO 892 and the reference to Whaun. DOCUMENT-IDENTIFIER: US H000271 H  
TITLE: Treatment of malaria with esters of cephalotaxineH000271. 18 Dec 85; 05 May 87. Whaun; June M..

Homoharringtonine was administered twice a day orally and subcutaneously in a volume of 10 ml/kg on the third, fourth and fifth days after inoculation of parasites. The homoharringtonine was mixed in aqueous 0.5% hydroxyethyl cellulose--0.1% Tween-80 and ultrasonicated when necessary. The doses were prepared using 100% free base of the drug. Groups 8 and 16 of the infected mice received the vehicle alone and served as a negative control. The blood films and final group weights were taken on the sixth day after inoculation of parasites. Microscope examination of Giensa-stained blood smears was made to determine the percent parasitemia (percentage of cells parasitized), and percent suppression of parasitemia. The percent suppression of parasitemia is determined by comparing the average parasitemia of the surviving mice with the parasitemia of the negative controls. Toxicity is attributed to drug action when a 14% or greater weight change occurs or when one or more mice die before the blood smears are taken. The results of the in vivo test are shown in Tables 2 and 3 and graphically in FIGS. 1 and 2 for subcutaneous and oral treatments respectively. An effective dosage occurs when the drug produces 90% suppression. This effective dosage for homoharringtonine given subcutaneously is 3.8 mg/kg per day and given orally is 2.8 mg/kg per day.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Lilling whose telephone number is 571-272-0918 and Fax Number is (703) 872-9306 or SPE Michael Wityshyn whose telephone number is 571-272-0926. Examiner can be reached Monday-Thursday from about 5:30 A.M. to about 3:00 P.M. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Information regarding the status of an application may be obtained from the Patent Application information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://portal.uspto.gov/external/portal/pair>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

H.J.Lilling: HJL  
(571) 272-0918  
Art Unit 1651  
March 28, 2006  
ATTACHMENT PTO 892

  
Herbert J. Lilling Primary Examiner Art Unit 1651